

26. Juli.2010

---

### **MPH Mittelständische Pharma Holding: Yearly Revenue from 2009 (5.079 TEuro) already topped in the first 6 months of 2010 (5.086 TEuro).**

Today, MPH Mittelständische Pharma Holding presents the figures until June 30<sup>th</sup> 2010.

The MPH Group has achieved a turn-over of 54,86 Mio. Euros in the first half of 2010 and a surplus of 5,09 Mio. Euros. The turn-over before taxes and interest rate was at 5,96 Mio. EUR (EBIT). The turn-over before taxes, interest, depreciation and amortization was at 6,07 Mio. EUR (EBITDA).

The profits of the MPH Group in the first half of 2010 were achieved entirely by the full subsidiary HAEMATO PHARM AG based in Schoenefeld. HAEMATO PHARM AG obtained a turn-over of 54,86 Mio EUR in the first 6 months in 2010 (81 % of the entire year 2009. 67,44 Mio. EUR) and a surplus of 5,32 Mio. EUR (entire year before 5,62 Mio. EUR). The profit before taxes and interest rate was 6,43 Mio EUR (EBIT) (entire year before 6,87 Mio. EUR). The turn-over before taxes, interest, depreciation and amortization was at 6,54 Mio. EUR (EBITDA) (entire year before 7,12 Mio. EUR).

More and more Pharmacists, Doctors and Patients trust in imported EU branded pharmaceuticals and generics. Because of this development, the company is certain to increase its turn-over in the financial year 2010 to over 100 Mio. EUR.

### **About MPH Mittelständische Pharma Holding AG:**

The Berlin based MPH Mittelständische Pharma Holding AG is concentrating on strategic growth segments in the Pharmaceutical sector. The core competences hereby lie in the licensing, procurement and production of pharmaceutical products.

With the help of the subsidiary company HAEMATO PHARM AG, the business fields of development, licensing of generics as well as the licensing of imports for EU branded pharmaceuticals are covered.

The product portfolio contains the therapeutic areas of oncology, HIV, neurology, cardio-vascular disease as well as rheumatism and is continuously being expanded.

#### **Kontakt:**

MPH Mittelständische Pharma Holding AG  
Hubertusallee 73  
D-14193 Berlin

Tel.: +49 (0) 30 897 30 86 60  
Fax: +49 (0) 30 897 30 86 70

E-Mail: [info@mph-ag.de](mailto:info@mph-ag.de)  
Web: [www.mph-ag.de](http://www.mph-ag.de)

26. Juli.2010

---

MPH Mittelständische Pharma Holding AG has been listed on the stock exchange (Open Market) in Frankfurt.

Key capital market data for MPH Mittelständische Pharma Holding AG:

Capital Stock: EUR 38.050.000

Listed class of shares: Owner held-preferred shares.

Number of free floating preference shares: 19.025.000

ISIN DE000AONF697

WKN AONF69

Stock Exchange abbreviation 93MV

**Contact:**

MPH Mittelständische Pharma Holding AG

Hubertusallee 73

14193 Berlin

Deutschland

Tel:+49 (0) 30 897308660

Fax:+49 (0) 30 897308670

E-Mail:[info@mph-ag.de](mailto:info@mph-ag.de)

Web:[www.mph-ag.de](http://www.mph-ag.de)

**Kontakt:**

MPH Mittelständische Pharma Holding AG

Hubertusallee 73

D-14193 Berlin

Tel.: +49 (0) 30 897 30 86 60

Fax: +49 (0) 30 897 30 86 70

E-Mail: [info@mph-ag.de](mailto:info@mph-ag.de)

Web: [www.mph-ag.de](http://www.mph-ag.de)